

1 **Title:** Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths
2 during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A
3 VEBIS-EHR Network Study

4 **Authors:** Baltazar Nunes^{1*}, James Humphreys¹, Nathalie Nicolay², Toon Braeye³, Izaak Van
5 Evercooren³, Christian Holm Hansen⁴, Ida Rask Moustsen-Helms⁴, Chiara Sacco^{5,6}, Massimo
6 Fabiani⁵, Jesús Castilla^{7,8}, Iván Martínez-Baz^{7,8}, Hinta Meijerink⁹, Ausenda Machado¹⁰, Patricia
7 Soares¹⁰, Rickard Ljung¹¹, Nicklas Pihlström¹¹, Anthony Nardone¹, Sabrina Bacci², Susana
8 Monge^{12,13}, VEBIS-EHR working group

9 * Corresponding author

10 **Affiliations**

11 ¹ Epiconcept, Paris, France

12 ² Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and
13 Control (ECDC), Solna, Sweden

14 ³ Sciensano, Juliette Wytsmanstraat 14. 1050 Elsene, Belgium

15 ⁴ Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut,
16 Copenhagen, Denmark

17 ⁵ Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy

18 ⁶ European Programme on Intervention Epidemiology Training (EPIET), European Centre for
19 Disease Prevention and Control, Stockholm, Sweden

20 ⁷ Instituto de Salud Pública de Navarra – IdiSNA, Pamplona, Spain

21 ⁸ CIBER on Epidemiology and Public Health, Spain

22 ⁹ Norwegian Institute of Public Health (NIPH), Oslo, Norway

23 ¹⁰ Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, 1600-609, Portugal

24 ¹¹ Swedish Medical Products Agency, Uppsala, Sweden

25 ¹² Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health

26 Carlos III, Madrid, Spain.

27 ¹³ CIBER on Infectious Diseases, Spain

28

29

30 **VEBIS-EHR working group:** Esther Kissling¹, Mario Fontán-Vela¹², Joris Van Loenhout³, Pierre

31 Hubin³, Alberto Mateo-Urdiales⁵, Daniele Petrone⁵, Patrizio Pezzotti⁵, Itziar Casado^{7,8}, Aitziber

32 Echeverria^{7,8}, Camino Trobajo-Sanmartín^{7,8}, Diana Lucas¹⁰.

33

34 **Corresponding author:**

35 Dr. Baltazar Nunes

36 Epiconcept, Paris, France

37 b.nunes@epiconcept.ft

38

39 **Word count:** 2,610

40 **Abstract word count:** 254

41 **Abstract**

42 Background

43 Monovalent XBB.1.5 vaccine was administered among those aged ≥ 65 years in EU/EEA countries
44 in autumn 2023; soon after SARS-Cov-2 BA.2.86/JN.1 lineages became dominant. We aimed to
45 estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalisations and
46 deaths during a period of BA.2.86/JN.1 predominance using a European multi-country study.

47 Methods

48 We linked electronic health record data to create historical cohorts in Belgium, Denmark, Italy,
49 Navarre (Spain), Norway, Portugal and Sweden. We included individuals aged ≥ 65 years eligible
50 for the autumnal 2023 COVID-19 vaccine with at least a primary series. Follow-up started when
51 $\geq 80\%$ of country-specific sequenced viruses were BA.2.86/JN.1 lineages (4/12/23 to 08/01/24)
52 and ended 25/02/2024. At study site level, we estimated the overall vaccine confounder-
53 adjusted (for age, sex, country's region, comorbidities and previous booster doses) hazard ratio
54 (aHR) of COVID-19 hospitalisations and deaths between individuals with ≥ 14 days after
55 vaccination and individuals unvaccinated in autumn 2023, as well as by time since vaccination
56 and stratified by age groups. VE was estimated as $(1 - \text{pooled aHR}) \times 100$ with a random effects
57 model.

58 Results

59 XBB.1.5 VE against COVID-19 hospitalisations was 50% (95%CI: 45 to 55) and 41% (95%CI: 35 to
60 46) in 65-79-year-olds and in ≥ 80 -year-olds respectively. VE against COVID-19-related-death was
61 58% (95%CI: 42 to 69) and 48% (95%CI: 38 to 57), respectively, in both age groups. VE estimates
62 against each respective outcome declined in all age group over time.

63 Conclusion

64 Monovalent XBB.1.5 vaccine had a moderate protective effect against severe COVID-19 likely
65 caused by BA.2.86/JN.1 during the 2023/2024 winter, among persons aged ≥ 65 .

66 **Keywords:** COVID-19, SARS-CoV-2, vaccine effectiveness, hospitalisation, cohort design,
67 electronic health records, multi-country study.

68 Introduction

69 In autumn 2023, COVID-19 vaccination campaigns were carried out in EU/EEA countries aiming
70 to reduce the risk of severe disease among the most vulnerable populations. The target groups
71 generally included those aged ≥ 60 or ≥ 65 years, persons living with comorbidities or conditions
72 that could increase the risk of severe disease, health professionals, and caregivers. The
73 monovalent Omicron XBB.1.5 vaccine was used in most EU/EEA countries and delivered as a
74 booster dose or primary vaccination during autumn/winter 2023/24. In January 2024 (1) the
75 median vaccine coverage among EU/EEA countries was 12% (range 0.01%–66.1%) and 17.1
76 (range 0.01%–89.3%), for those aged ≥ 60 or ≥ 80 years respectively - a range which indicates
77 variability between countries in terms of vaccine uptake. Eighty-two percent of the vaccines
78 administered during the autumn/winter 2023/24 campaign were Comirnaty Omicron XBB.1.5
79 (Pfizer BioNTech) vaccine (1).

80 In early autumn 2023, in EU/EEA countries, the XBB.1.5 lineage was predominant. The BA.2.86
81 and JN.1 SARS-CoV-2 lineages rapidly increased, gaining dominance in all EU/EEA countries by
82 mid-December (2).

83 Several studies reported XBB.1.5 vaccine effectiveness (VE) against severe disease in the first
84 months of the autumn/winter season at a time of XBB.1.5 predominance (3–6), including one
85 study conducted within the Vaccine Effectiveness Burden and Impact Studies project EHR
86 network (VEBIS-EHR) (4). These studies reported VE against COVID-19 hospitalisations ranging
87 between 62% to 74%, 52% to 74%, and 52% to 66% among those aged ≥ 18 , ≥ 65 and ≥ 80 years
88 old respectively.

89 The BA.2.86 SARS-CoV-2 lineage presents more than 30 amino acid mutations compared to the
90 XBB.1.5 lineage, and JN.1, a descendant of BA.2.86, harbours the L455S substitution at the
91 receptor binding site. These mutations could provide immune escape capacities and reduce the
92 effectiveness of the XBB.1.5 vaccine (7). However, studies of XBB.1.5 VE against severe disease

93 during periods of BA.2.86 or JN.1 predominance are still scarce (5,8). In this context, we aimed
94 to estimate XBB.1.5 VE against COVID-19-related hospitalisations and deaths overall and by time
95 since vaccination during a period of BA.2.86/JN.1 predominance within a European multi-
96 country study among older adults aged 65-79 and ≥ 80 years old.

97 **Methods**

98 This study was developed under the VEBIS-EHR network. The VEBIS project, funded by the
99 European Centre for Prevention and Disease Control (ECDC), aims to monitor COVID-19 VE using
100 linkage of electronic health records (EHR) within an EU/EEA multi-country setting. As of April
101 2024, seven countries participate in the VEBIS-EHR network: Belgium, Denmark, Italy, Spain
102 (Navarre), Norway, Portugal, and Sweden.

103 Detailed methods and the results of VEBIS-EHR studies have been published previously (9–11).
104 Briefly, using a common protocol (12) we developed a historical cohort study by reconstructing
105 study site cohorts of individuals aged 65 years or older resident in the and eligible to receive the
106 autumnal 2023 vaccine dose at the start of the country-specific vaccination campaign
107 (Supplementary material, Table S1, Annex 1), i.e., those aged 65 years or older, with primary
108 vaccination series completed at least 180 days ago and who, in the last 90 days, had no vaccine
109 dose administered nor documented SARS-CoV-2 infection or COVID-19 hospitalisation. Detailed
110 information on the eligibility criteria is presented in the Supplementary material, Annex 2.
111 Vaccination status, baseline characteristics, and outcome occurrence were obtained by linking
112 national/regional EHR. We defined BA.2.86/JN.1 lineage predominance period at the study-site
113 level, designating the period of predominance to have started by the date on which 80% of
114 sequenced samples were attributable to BA.2.86/JN.1 based on data extracted from the ECDC
115 European Respiratory Virus Surveillance Summary (ERVISS)(13) database and subset to the
116 countries of interest.

117 If the number of the weekly sequenced viruses was low, BA.2.86 frequency data from
118 neighbouring countries were used as a proxy (Supplementary material, Annex 1). In Table S1 we
119 present details on the start of BA.2.86 predominance period by study site. The end of the study
120 period was 25 February in all study sites, approximately two months before data extraction
121 (April 2024) to ensure EHR were sufficiently updated.

122 Among those identified as eligible at the start of the vaccination campaign (Supplementary
123 material, Annex 2), we excluded all individuals hospitalised due to COVID-19 between the start
124 of the vaccination campaign and the country-specific starting date of the study. Individual
125 follow-up started at the beginning of the country-specific study period and ceased at the date
126 of either the outcome, death for any cause, or the end of the study period - whichever was
127 earliest. Vaccination status was treated as a time-dependent exposure, excluding the time-
128 interval 1-14 days post-vaccination from the analysis.

129 Hospitalisation due to COVID-19 was defined as a hospital admission due to a severe acute
130 respiratory infection with a SARS-CoV-2 positive test from 14 days before to one day after
131 admission, or with COVID-19 as the primary diagnosis in admission on discharge records. A
132 COVID-19-related death was defined as a death with COVID-19 coded as cause, or death for any
133 cause with a SARS-CoV-2 positive test in the 30 days preceding death.

134 We undertook a two-stage pooling of estimates calculated at the study-site level. In the first
135 stage, site-specific estimates of confounder-adjusted vaccine hazard ratios (aHR) and 95%
136 confidence intervals (95%CI) were calculated using Cox regression with calendar time as the
137 underlying scale adjusted by 5-year age groups, sex, region in the country, comorbidities,
138 number of vaccine booster doses received prior to the current vaccination campaign, and
139 nationality and socioeconomic status in some of the study sites (Supplementary material, Annex
140 3 and 4). In the second stage, study site-specific aHR estimates and standard errors were pooled
141 using a random-effects meta-analysis using Paule-Mantel method. Pooled VE was estimated as

142 (1-pooled aHR)x100. To assess heterogeneity, we used the I² index (14). A fixed-effects model
143 was used as a secondary analysis.

144 **Results**

145 At the end of the individual observation period, we included 13,907,924 and 6,533,724 persons
146 across both age groups, in the unvaccinated and vaccinated cohorts, respectively. Among the
147 vaccinated cohorts, at the end of the observation period, 2,604,152 (39.9%) and 3,929,572
148 (60.1%) belonged, respectively, to those who were vaccinated 14 to 89 days and 90 to 179 days.

149 The proportion of individuals with high-risk comorbidities (7.3% vs 2.6%) and with a greater
150 number of previous booster doses (≥ 2 boosters: 92.3% vs 33.1%) was higher among vaccinated
151 than unvaccinated. Further, but to a lesser extent, vaccinated persons with a longer time since
152 vaccination (90-179 days) also had a greater frequency of high-risk comorbidities (9.0% vs 4.8%)
153 and a greater number of previous boosters (≥ 2 boosters: 94.3% vs 89.4%) doses compared to
154 those vaccinated with less time since vaccination (14-90 days) (Table 1).

155 In the 65-79 years age group there were 1,765 hospitalisation events among 17.8 million person-
156 months at risk in unvaccinated, and 908 COVID-19 hospitalisations events among 9.9 million
157 person-months at risk in vaccinated persons. XBB.1.5 COVID-19 VE against COVID-19
158 hospitalisations was 50% (95%CI: 45 to 55) overall, 51% (95%CI: 45 to 56) and 47% (95%CI: 32 to
159 59) among those who received the vaccine respectively between 14 to 89 days and 90 to 179
160 days.

161 In ≥ 80 years age-group, there were 2,130 COVID-19 hospitalisation events among 7.0 million
162 person-months at risk in unvaccinated, and 1,306 among 4.1 million person-months at risk in
163 vaccinated persons. VE was 41% (95%CI: 35 to 46) overall and 42% (95%CI: 36 to 47) and 38%
164 (95%CI: 17 to 54%) by time since vaccination among those who received the vaccine between
165 14 to 89 days and 90 to 179 days, respectively.

166 In the 65–79-year age-group there were 256 COVID-19 related deaths among 15.9 million
167 person-months at risk in unvaccinated, and 151 among 7.8 million person-months at risk in
168 vaccinated individuals. XBB.1.5 COVID-19 VE estimates against COVID-19-related deaths, was
169 58% (95%CI: 42 to 69) overall, 59% (95%CI: 41 to 72) and 54% (95%CI: -17 to 82) respectively
170 among those who received the vaccine between 14 to 89 days and 90 to 179 days.

171 In the ≥ 80 -year age-group, there were 570 COVID-19 related deaths event among 6.6 million
172 person-months at risk in unvaccinated, and 389 among 3.4 million person-months at risk in
173 unvaccinated persons. The XBB.1.5 COVID-19 was 48% (95%CI: 38 to 57) overall, 51% (95%CI: 42
174 to 59) and 9% (95%CI: -86 to 56%) among those who received the vaccine between 14 to 89 days
175 and 90 to 179 days, respectively (Table 2).

176 There was low to moderate heterogeneity between study sites' aHR estimates among pooled
177 VE estimates ($I^2=0\%$ to 77%). High heterogeneity ($I^2=77\%$) was observed in the VE estimate
178 against death within 90-179 days since vaccination for the 80+ cohort, leading to a very wide
179 95% confidence interval for this estimate. Fixed effects pooled estimates were similar to the
180 random effect estimates presented in the primary analysis (Supplementary figures – Annex 6).

181 **Discussion**

182 Our results indicate that in the population aged 65 years and older, the 2023 autumnal
183 monovalent XBB.1.5 booster conferred protection against severe COVID-19 outcomes during
184 the period in which COVID-19 cases were likely to be caused by the Omicron BA.2.86 or JN.1
185 lineages. These estimates of protection represent a reduction in risk that ranged from 42% to
186 51% for COVID-19 hospitalisation and from 51 to 59% for COVID-19 deaths for those who
187 received the vaccine in the last three months, and were consistently lower among those aged
188 ≥ 80 years. For those vaccinated, but with more time since vaccination (three or more months)
189 during the BA.2.86/JN.1 predominance period, XBB.1.5 vaccine presented lower levels of
190 protection against COVID-19 hospitalisations, ranging from 38% to 47%, and against COVID-19

191 related deaths ranging from 9% to 54% though, as discussed earlier, the latter estimates against
192 COVID-19-related deaths had low precision.

193 Our results suggest a lower VE among those who received a vaccine between 14 and 89 days in
194 the BA.2.86/JN.1 predominant period, compared to the XBB predominant period estimates
195 obtained in the VEBIS-EHR network (4). Specifically, in the 65–79-year-old XBB.1.5 VE against
196 hospitalisations decreased from 64% (95%CI 55 to 72) in the XBB period to 51% (95%CI 45 to 56)
197 in the BA 2.86/JN1 period and for those ≥ 80 years from 65% (95%CI 56 to 71) to 42% (95%CI 36
198 to 47). The XBB.1.5 VE against COVID-19-related deaths declined in those aged 65-79 years from
199 67% (95%CI: 42 to 81) to 59% (95%CI 41 to 72) and in those ≥ 80 years from 67% (95%CI: 41 to
200 81) to 51% (95%CI: 42 to 59). These differences could be due to higher natural immunity in the
201 comparison group due to recent SARS-CoV-2 infection, although other studies employing
202 different study designs have also found evidence of reduced vaccine effectiveness against
203 BA.2.86/JN.1 relative to XBB.1.5 (15).

204 Our results are concordant with results from other studies that estimated COVID-19 VE against
205 severe outcomes potentially due to XBB sub-lineages or JN.1 SARS-CoV-2 lineages. A test-
206 negative design study conducted in England (8) in the population aged 65 years or more showed
207 a decrease in VE against hospitalisations from 74% (95%CI: 62% to 82%) against XBB sub-lineages
208 to 37% (95%CI: -20 to 66) against JN.1, for those who were vaccinated 2-4 weeks after
209 vaccination before. Similar results were also observed in two studies conducted in the United
210 States (5,6) that aimed to estimate XBB.1.5 VE against hospitalisations likely due to XBB sub-
211 lineages versus JN.1 among individuals aged ≥ 18 years. In both studies, a reduction in the
212 protection of XBB.1.5 vaccine against COVID-19 hospitalisations was observed within the first 60
213 days after vaccination, respectively from 62% (95%CI: 44% to 74%) to 32% (95%CI: 3% to 52%)
214 (5), and from 74% (95%CI: 49% to 87%) to 50% (95%CI: 15% to 71%) (6).

215 The results presented here should be interpreted cautiously, considering the potential presence
216 of confounding bias, given its observational nature, and the possible misclassification of the
217 vaccine status and outcome once we used an EHR-based multicentre study. The vaccine status
218 hazard ratios were adjusted for several potential confounding factors at the study site level. Still,
219 although this adjustment was made, we cannot exclude the presence of confounding residual
220 bias from our analysis. Considering misclassification of the exposure, vaccination information
221 was extracted from national vaccination registries and measured prior to, and independently of,
222 the outcome. Estimates of 2023 autumnal COVID-19 vaccine coverage observed within our EHR-
223 based study population were very close to the officially reported equivalents produced by the
224 ECDC (Supplementary, Annex 6, Table S5). We considered our VE estimate representative of
225 XBB.1.5 vaccine performance given that 98.3% (Table 1) of the vaccines received during the
226 study period were the monovalent XBB.1.5. Among these, 99% were the Pfizer Comirnaty
227 XBB.1.5-adapted vaccine, which indicates that our VE estimates represent the effectiveness of
228 this vaccine brand in general.

229 Additionally, we cannot rule out the presence of misclassification or underreporting of COVID-
230 19 hospitalisations and deaths, even using national hospitalisations, death and laboratory
231 registries given the lag between event and full recording of such events in the relevant EHRs,
232 and also due the reduction in SARS-CoV-2 testing that would underestimate COVID-19 related
233 deaths identification. To reduce the effect of misclassification bias due to unextracted events,
234 or otherwise due to extraction of incomplete records, a two-month delay between the end of
235 the study period (i.e., the last possible event) and extraction of data from source EHRs has been
236 implemented. For the purpose of this analysis, no EHR extractions were undertaken until at least
237 April 2024. Nevertheless, we do not expect that misclassification of the outcome could be
238 differential by the vaccine status. If underreporting of events is present in our data, we do not
239 expect a bias to arise from it, only a loss in the number of events and statistical power. On the

240 other hand, if non-COVID-19 hospitalisation are classified as COVID-19 event, we expect that our
241 estimates would be biased to the null effect (16).

242 Another issue to be addressed, will be the high diffusion of self-diagnosis through at-home
243 testing and the possible under-ascertainment of asymptomatic and mild cases, it is likely that
244 some SARS-CoV-2 infections were not reported, thus leading to a possible overestimation of the
245 eligible individuals at the start of the vaccination campaigns. This was likely more frequent in
246 those who did not receive the seasonal booster, possibly causing an underestimation of VE.

247 The comparison of VE by time since XBB.1.5 administration among different epidemic phases,
248 like XBB vs BA.2.86 predominance periods, should be interpreted with cautions because of the
249 possible different unmeasured characteristics among persons who received the seasonal
250 booster at different times. For example, those who received the booster dose later might be
251 generally less prone to adopt preventive measures and therefore have had a higher exposure to
252 risky behaviours than those who received it earlier. Additionally, individuals with a recent
253 infection will be higher among unvaccinated persons during BA.2.86/JN.1 period. Both these
254 situations could have resulted in a relative underestimation of VE during the BA.2.86/JN.1
255 predominance period, and a slight overestimation of VE in the XBB predominance period.

256 Despite the limitations described above, our study also has several strengths. As we employed
257 mostly national registries, large sample sizes and a large number of events were reported by
258 study sites, leading to a high precision around VE estimates and allowing stratified VE estimates.
259 Additionally, the fact that the study was conducted in seven different EU/EEA countries using a
260 common scientific protocol published ahead of the study development (12), and the low to
261 moderate heterogeneity observed between study-level VE estimates, reinforce the consistency
262 and reproducibility of the results in the participating study sites.

263 In conclusion, our XBB.1.5 VE estimates against severe COVID-19, likely caused by BA.2.86/JN.1,
264 were lower than those observed during the XBB.1.5 lineage predominance period. Nevertheless,

265 the results of our study indicate that the XBB.1.5 vaccine offered moderate protection ($\geq 40\%$)
266 for up to six months after vaccination against severe COVID-19, likely caused by BA.2.86/JN.1,
267 during the 2023/2024 winter in older (≥ 65 years old) populations.

268 **Acknowledgments**

269 The authors would like to thank all the people from the study sites involved in the data collection
270 and for producing estimates of VE, as without their work these results wouldn't be available for
271 the scientific community and the public.

272 We gratefully acknowledge all data contributors, i.e., the Authors and their Originating
273 laboratories responsible for obtaining the specimens, and their Submitting laboratories for
274 generating the genetic sequence and metadata and sharing via the GISAID Initiative, on which
275 this research is based.

276 **Ethics**

277 All study sites participating in this study conformed with their respective national and EU ethical
278 and data protection requirements. Ethical statements for each of the participating study sites:

279 **Belgium:** Data linkage and collection within the data-warehouse have been approved by the
280 information security committee. The study was conducted in accordance with the Declaration
281 of Helsinki. Ethical approval was granted for the gathering of data from hospitalized patients by
282 the Committee for Medical Ethics from the Ghent University Hospital (reference number BC-
283 07507) and authorization for possible individual data linkage using the national register number
284 from the Information Security Committee (ISC) Social Security and Health (reference number
285 IVC/KSZG/20/384). Linkage of hospitalized patient data to vaccination and testing within the
286 LINK-VACC project was approved by the Medical Ethics Committee UZ Brussels–VUB on 3
287 February 2021 (reference number 2020/523), and authorization from the ISC Social Security and
288 Health (reference number IVC/KSZG/21/034).

289 **Denmark:** Only administrative register data was used for the study. According to Danish law,
290 ethics approval is exempt for such research, and the Danish Data Protection Agency, which is
291 dedicated ethics and legal oversight body, thus waives ethical approval for the study of
292 administrative register data when no individual contact of participants is necessary, and only
293 aggregate results are included as findings. The study is, therefore, fully compliant with all legal
294 and ethical requirements, and there are no further processes available regarding such studies.

295 **Navarre (Spain):** The study was approved by Navarre's Ethical Committee for Clinical Research,
296 which waived the requirement of obtaining informed consent.

297 **Norway:** Ethical approval was granted by Regional Committees for Medical and Health Research
298 Ethics (REC) Southeast (reference number 122745). The Norwegian Institute of Public Health has
299 performed a Data Protection Impact Assessment (DPIA) for Beredt C19.

300 **Portugal:** The study received approval from the Ethical Committee and the Data Protection
301 Officer of the Instituto Nacional de Saúde Doutor Ricardo Jorge. Given that data was irreversibly
302 anonymised, the need for the participants' informed consent was waived by the Ethical
303 Committee.

304 **Italy:** This study, based on routinely collected data, will not be submitted for approval to an
305 ethical committee because the dissemination of COVID-19 surveillance data was authorized by
306 the Italian law N. 52 of 19 May 2022, following the law decree N. 24 of 24 March 2022 (Article
307 n. 13). Based on the same acts, the information on COVID-19 vaccination was retrieved by the
308 Italian National Institute of Health using data from the National Immunisation Information
309 System of the Italian Ministry of Health. Because of the retrospective design and the large size
310 of the population under study, in accordance with the Authorization n. 9 released by the Italian
311 data protection authority on 15 December 2016, the individual informed consent was not
312 requested for the conduction of this study.

313 **Sweden:** The Swedish study is approved by the Swedish Ethical Review Authority (2020-06859,
314 2021-02186) and has conformed to the principles embodied in the Declaration of Helsinki.
315 Consent to participate is not applicable as this is a register-based study.

316 **Funding**

317 All the public health organizations involved received funding from the European Centre for
318 Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/018
319 ‘Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure
320 and outcome using health registries’ (RS/2022/DTS/24104). In Portugal, this work was also
321 supported by FCT – Fundação para a Ciência e Tecnologia, I.P. by project reference
322 CEECINST/00049/2021/CP2817/CT0001 and DOI identifier
323 10.54499/CEECINST/00049/2021/CP2817/CT0001

324 **Data Availability:** Authors cannot share the data used for this study, which should be requested
325 to the data owner institutions following their respective procedures.

326 **Conflict of interest:** Authors declare no competing interests.

327 **Author contribution:** SB, NN, BN, JH and SM conceived the study and BN, JH, NN and SM
328 conceived the methods. All authors from Public Health institutions at each study site were
329 responsible for the data management and analysis at the site level. JH was in charge of pooling
330 site estimates, with the help of SM. BN drafted the first version of the manuscript, with the help
331 of JH and SM, AN, and EK. All the authors contributed to the interpretation of the results and
332 critically reviewed the manuscript. All the authors approved the final version of this manuscript.
333 All the authors within the VEBIS-EHR working group made a substantial contribution to the
334 conception or design of the work, critically revised the manuscript, provided their final approval
335 of the version to be published, and agreed to be accountable for all aspects of the work.

336 **References**

337 1. European Centre for Disease Prevention and Control. Interim COVID-19 vaccination
338 coverage in the EU/EEA during the 2023–24 season campaigns [Internet]. ECDC; 2024
339 [cited 2024 May 28]. Available from: [https://www.ecdc.europa.eu/en/publications-](https://www.ecdc.europa.eu/en/publications-data/interim-covid-19-vaccination-coverage-eueea-during-2023-24-season-campaigns)
340 [data/interim-covid-19-vaccination-coverage-eueea-during-2023-24-season-campaigns](https://www.ecdc.europa.eu/en/publications-data/interim-covid-19-vaccination-coverage-eueea-during-2023-24-season-campaigns)

- 341 2. European Centre for Disease Prevention and Control. Communicable disease threats
342 report, 17-23 December 2023, week 51. ECDC; 2023.
- 343 3. Hansen CH, Moustsen-Helms IR, Rasmussen M, Søbørg B, Ullum H, Valentiner-Branth P.
344 Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation
345 in Denmark: a national cohort study. *Lancet Infect Dis*. 2024 Feb 1;24(2):e73–4.
- 346 4. Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.
347 Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5
348 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network
349 Study. *Influenza Other Respir Viruses*. 2024 Apr;18(4):e13292.
- 350 5. Caffrey AR, Appaneal HJ, Lopes VV, Puzniak L, Zasowski EJ, Jodar L, et al. Effectiveness of
351 BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System. *medRxiv*. 2024 Jan
352 1;2024.04.05.24305063.
- 353 6. Tartof SY, Slezak JM, Puzniak L, Frankland TB, Ackerson BK, Jodar L, et al. Effectiveness of
354 BNT162b2 XBB Vaccine against XBB and JN.1 Sub-lineages. *medRxiv*. 2024 Jan
355 1;2024.05.04.24306875.
- 356 7. Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, et al. Fast evolution of SARS-CoV-2 BA.2.86
357 to JN.1 under heavy immune pressure. *Lancet Infect Dis*. 2024 Feb 1;24(2):e70–2.
- 358 8. Kirsebom FCM, Stowe J, Lopez Bernal J, Allen A, Andrews N. Effectiveness of autumn 2023
359 COVID-19 vaccination and residual protection of prior doses against hospitalisation in
360 England, estimated using a test-negative case-control study. *J Infect*. 2024 May
361 7;89(1):106177.
- 362 9. Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, et al. Estimation of
363 COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using
364 electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March
365 2022. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2022 Jul;27(30).
- 366 10. Kislaya I, Sentís A, Starrfelt J, Nunes B, Martínez-Baz I, Nielsen KF, et al. Monitoring COVID-
367 19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic
368 health registries in ≥ 65 years old population in six European countries, October 2021 to
369 November 2022. *Influenza Other Respir Viruses*. 2023 Nov;17(11):e13195.
- 370 11. Fontán-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.
371 Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years:
372 results from a VEBIS network, Europe, October 2021 to July 2023. Vol. 29,
373 *Eurosurveillance*. 2024. p. 2300670.
- 374 12. European Centre for Disease Prevention and Control. Protocol for a COVID-19 vaccine
375 effectiveness estimation using health data registries, VEBIS multi-country study - Version
376 2.0 [Internet]. ECDC; 2024 [cited 2024 May 28]. Available from:
377 [https://www.ecdc.europa.eu/en/publications-data/protocol-covid-19-vaccine-](https://www.ecdc.europa.eu/en/publications-data/protocol-covid-19-vaccine-effectiveness-estimation-using-health-data-registries)
378 [effectiveness-estimation-using-health-data-registries](https://www.ecdc.europa.eu/en/publications-data/protocol-covid-19-vaccine-effectiveness-estimation-using-health-data-registries)
- 379 13. European Centre for Disease Prevention and Control. European Respiratory Virus
380 Surveillance Summary (ERVISS) [Internet]. 2024 [cited 2024 Jun 27]. Available from:
381 <https://erviss.org/>

- 382 14. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002
383 Jun 15;21(11):1539–58.
- 384 15. Moustsen-Helms IR, Bager P, Larsen TG, Møller FT, Vestergaard LS, Rasmussen M, et al.
385 Relative vaccine protection, disease severity, and symptoms associated with the SARS-
386 CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide
387 observational study. *Lancet Infect Dis* [Internet]. [cited 2024 Jun 20]; Available from:
388 [https://doi.org/10.1016/S1473-3099\(24\)00220-2](https://doi.org/10.1016/S1473-3099(24)00220-2)
- 389 16. Hansen CH. Bias in vaccine effectiveness studies of clinically severe outcomes that are
390 measured with low specificity: the example of COVID-19-related hospitalisation. *Euro*
391 *Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2024 Feb;29(7).

392

393 **Table 1.** Descriptive characteristics of the study population (N= 20,441,648) by vaccination
 394 status and time since vaccination at the end of the study period*, within the seven study sites
 395 (Belgium, Denmark, Italy, Navarre-Spain, Norway, Portugal, and Sweden during BA.2.86/JN.1
 396 predominant period (from 4 December 2023 until 25 February 2024): VEBIS-EHR network.

Variable	Not vaccinated n (%)	Vaccinated ≥14 days n (%)	Vaccinated 14-89 days n (%)	Vaccinated 90-179 days n (%)
Total (row % over total = 20,440,689)	13,907,924 (68)	6,533,724 (32.0)	2,604,152 (21.7)	3,929,572 (25.2)
Study site				
Belgium	936,583 (6.7)	1,065,561 (16.3)	75,731 (2.9)	989,830 (25.2)
Denmark	219,481 (1.6)	894,411 (13.7)	100,989 (3.9)	793,422 (20.2)
Italy	10,750,561 (77.3)	1,296,464 (19.8)	984,379 (37.8)	312,085 (7.9)
Navarre	45,563 (0.3)	154,610 (2.4)	80,262 (3.1)	74,348 (1.9)
Norway	397,240 (2.9)	525,048 (8.0)	160,684 (6.2)	364,364 (9.3)
Portugal	1,100,849 (7.9)	1,251,091 (19.2)	325,366 (12.5)	925,725 (23.6)
Sweden	457,647 (3.3)	1,346,539 (20.6)	876,741 (33.7)	469,798 (12.0)
Age group (years)				
65-79	9,849,304 (70.8)	4,560,138 (69.8)	1,796,923 (69.0)	2,763,215 (70.3)
≥80	4,058,620 (29.2)	1,973,586 (30.2)	807,229 (31.0)	1,166,357 (29.7)
Sex				
Male	7,760,080 (55.8)	3,428,717 (52.5)	1,344,981 (51.6)	2,083,736 (53.0)
Female	6,147,822 (44.2)	3,105,006 (47.5)	1,259,171 (48.4)	1,845,835 (47.0)
Missing	22 (0.0)	1 (0.0)	0 (0.0)	1 (0.0)
Comorbidities**				
High risk comorbidities	355,038 (2.6)	478,559 (7.3)	123,707 (4.8)	354,852 (9.0)
Medium/low risk comorbidities	4,947,387 (35.6)	3,256,826 (49.8)	1,201,668 (46.1)	2,055,158 (52.3)
No comorbidities	8,579,525 (61.7)	2,783,512 (42.6)	1,276,771 (49.0)	1,506,741 (38.3)
Missing	25,974 (0.2)	14,827 (0.2)	2,006 (0.1)	12,821 (0.3)
Number of previous booster doses				
0	1,598,896 (11.5)	31,608 (0.5)	16,461 (0.6)	15,147 (0.4)
1	7,711,858 (55.4)	467,250 (7.2)	259,506 (10.0)	207,744 (5.3)
2	4,033,888 (29.0)	4,229,639 (64.7)	1,443,946 (55.5)	2,785,693 (70.9)
3	546,308 (3.9)	1,507,255 (23.1)	721,889 (27.7)	785,366 (20.0)
4	16,925 (0.1)	296,458 (4.5)	161,663 (6.2)	134,795 (3.4)
5	44 (0.0)	1,514 (0.0)	687 (0.0)	827 (0.0)
Missing	5 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Vaccine product				
Pfizer (monovalent)		75,915 (1.2)	13,953 (0.5)	61,962 (1.6)
Moderna (monovalent)		139 (0.0)	79 (0.0)	60 (0.0)
Pfizer (bivalent original/BA.1)		4,691 (0.1)	676 (0.0)	4,015 (0.1)
Moderna (bivalent original/BA.1)		11 (0.0)	1 (0.0)	10 (0.0)
Pfizer (bivalent original/BA.4/BA.5)		24,963 (0.4)	2,561 (0.1)	22,402 (0.6)
Moderna (bivalent original/BA.4/BA.5)		98 (0.0)	5 (0.0)	93 (0.0)
Pfizer (XBB.1.5)		6,373,342 (97.5)	2,581,821 (98.8)	3,791,521 (96.5)
Moderna (XBB.1.5)		49,597 (0.8)	99 (0.0)	49,498 (1.4)
Novavax		4,950 (0.1)	4,950 (0.3)	0 (0.0)
Other (AZ, others...)		3 (0.0)	2 (0.0)	1 (0.0)
Missing		15 (0.0)	5 (0.0)	10 (0.0)

* Vaccination status and time since vaccination were assessed at the end of the individual observation period

** High risk comorbidities: immunocompromised conditions with COVID-19 vaccine recommendation; Medium/low risk: non-immunocompromised conditions with COVID-19 vaccine recommendation; No comorbidities: persons without any of the risk comorbidities. (Details are presented in Supplementary material, Annex 3, Table S3)

398 **Table 2.** Number of events (COVID-19 hospitalisations or COVID-19 related deaths), person months at risk
 399 by vaccine status, and vaccine effectiveness overall and by time since vaccination for individuals aged 65-
 400 79 and ≥80 years old, within the seven study sites (Belgium, Denmark, Italy, Navarre-Spain, Norway,
 401 Portugal, and Sweden), during BA.2.86/JN.1 predominance period up to 25 February 2024, VEBIS-EHR
 402 network

	Events	Person-month	VE (95%CI)	Heterogeneity I ² (min-max study level VE estimates)
Age group 65-79				
Hospitalisations				
Not yet vaccinated	1765	17,778,199	ref	ref
Overall vaccinated (≥14 days)	908	9,962,714	50.2% (44.6; 55.2)	0% (45.3%, NV to 60%, BE)
Vaccinated (14-89 days)	813	6,476,931	50.9% (45.1; 56.1)	0% (48%, NO to 62%, BE)
Vaccinated (90-179 days)	91	2,801,147	47.3% (32; 59.1)	0% (-30.1%, NV to 67%, SE)
Deaths				
Not yet vaccinated	256	15,892,126	ref	ref
Overall vaccinated (≥14 days)	151	7,827,952	57.5% (41.5; 69.1)	23.2% (17%, SE to 68.1%, DK)
Vaccinated (14-89 days)	130	4,557,449	59.2% (41.3; 71.7)	32.9% (25%, SE to 68%, PT)
Vaccinated (90-179 days)	7	778,475	54.0% (-16.8; 81.9)	0% (54%, PT to 54%, PT)
Age group ≥80 years				
Hospitalisations				
Not yet vaccinated	2130	7,011,410	ref	ref
Overall vaccinated (≥14 days)	1306	4,111,559	40.7% (35; 45.8)	0% (29%, BE to 48%, DK)
Vaccinated (14-89 days)	1167	2,664,791	42.0% (36.3; 47.1)	0% (25%, BE to 48.2%, NV)
Vaccinated (90-179 days)	139	1,447,525	35.9% (11.2; 53.7)	38.6% (-1%, IT to 68.5%, DK)
Deaths				
Not yet vaccinated	570	6,576,524	ref	ref
Overall vaccinated (≥14 days)	389	3,435,771	48.4% (38.4; 56.8)	10.1% (36%, NO to 70%, SE)
Vaccinated (14-89 days)	330	2,407,183	51.2% (41.9; 59)	0% (43%, NO to 71%, SE)
Vaccinated (90-179 days)	55	856,482	9.4% (-85.5; 55.8)	77.2% (-159%, IT to 51%, PT)

VE: vaccine effectiveness, CI: Confidence Interval, BE: Belgium, DK: Denmark, IT: Italy; NO: Norway, NV: Navarre, PT: Portugal, SE: Sweden

VE = one minus the pooled confounder-adjusted hazard ratio at study level using a Cox regression time dependent model (confounder variables used in each study site are available in Annex 3 and 4 of the Supplementary material).

403